NYC Mayor De Blasio Tells Citizens: We Own Your Bodies, And

New Post Public Reply Private Reply Replies (1) Message Board
Lmcat
497
NYC Mayor De Blasio Tells Citizens: We Own Your Bodies, And We Can Force You To Be Injected With Anything We Want
April 16, 2019

NYC Mayor Bill de Blasio has declared that residents do not own their own bodies. The city of New York can demand that all citizens be injected with literally anything the government declares to be a “vaccine,” even when those vaccines contain aborted human fetal tissue cells, toxic aluminum metals, inflammatory adjuvants and other dangerous, deadly chemicals.

This is the latest attempt by authorities in New York to obliterate human rights and roll out a medical dictatorship where citizens have zero rights to defend their own bodies against risky medial interventions that are demanded at gunpoint.

PJ Media, which has emerged as one of the best independent media websites covering liberty and individual rights, has published an especially noteworthy article on this issue. Authored by Megan Fox, the story is entitled, “Mayor Bill de Blasio’s Mandatory Measles Vaccination Order Faces Legal Challenges.”

We are republishing it here with full credit to the original author and PJ Media website. This in important read. Share everywhere.
Mayor Bill de Blasio’s Mandatory Measles Vaccination Order Faces Legal Challenges

by Megan Fox, PJMedia.com

In an unusual and extreme move, New York Mayor Bill de Blasio declared a state of emergency over a measles outbreak in the Orthodox Jewish community and is demanding forced vaccinations of everyone within four zip codes of the affected areas. Violators face fines up to $1000. This includes babies six months of age, even though the MMR is not recommended for anyone under twelve months of age.

The Children’s Health Defense will be filing a legal challenge to the order, which comes on the heels of a New York Supreme Court ruling that struck down the Rockland County banon unvaccinated children in public spaces.

Children’s Health Defense (CHD) is supporting a legal challenge to this dangerous, unprecedented overreach. While the City has unquestionable authority to control disease outbreaks, it may not violate the bedrock principle of prior, free and informed consent to all medical interventions, including vaccines. This is a fundamental human right. The City may quarantine, isolate, trace contacts and strongly urge vaccination, but it may not impose such a draconian mandate without demonstrating necessity, reasonableness, proportionality, harm avoidance, non-discrimination, due process and equal protection. The Commissioner has failed to do this; the City’s actions violate New York State law.

CHD board member Mary Holland commented, “I am shocked that Mayor de Blasio would resort to such police state techniques to control an outbreak of measles. I don’t believe the City’s actions will withstand legal scrutiny.” CHD Chairman Robert F. Kennedy Jr. is confident their legal challenge will prevail.

This case goes beyond a dispute over religious freedom. Thanks to the Merck federal whistleblower litigation, we now know that Merck’s MMR should have never been approved, much less mandated. To get its license Merck allegedly ordered its scientists to falsify efficacy data to fraudulently conceal the fact that the mumps component quickly wanes, triggering dangerous outbreaks in older populations where it can cause sterility in men and women. The Centers for Disease Control and Prevention (CDC) reported 150 outbreaks resulting in 9,200 cases of mumps in fully vaccinated adults, dwarfing the recent measles outbreaks. We are confident that no American court will allow government bureaucrats to force American citizens to take risky pharmaceutical products against their will.

Merck is currently defending itself against claims of falsifying data brought by two former employees.

Medical corporation Merck & Co. will decidedly face the music in the ongoing class action and related anti-trust lawsuit involving its mumps vaccine – a product routinely given to babies and children for generations. The issue, which involves allegations of false compliance with FDA standards for vaccines, prompted a False Claims Act lawsuit: United States v. Merck & Co. This case was commenced by two virologists once employed with Merck, alleges a systematic and long-standing commitment by the company to lying about the efficacy of its mumps vaccination, thereby prompting possible exposure to liability under the federal False Claims Act.

Governor Cuomo voiced concerns about the legality of de Blasio’s emergency order to forcibly vaccinate conscientious objectors. “

Look, it’s a serious public health concern, but it’s also a serious First Amendment issue and it is going to be a constitutional, legal question,” Cuomo said in a radio interview on WAMC. “Do we have the right — does society, government have the right to say ‘you must vaccinate your child because I’m afraid your child is going to infect my child, even if you don’t want it done and even if it violates your religious beliefs?”

Some have asked how de Blasio is planning to determine who is or isn’t vaccinated to enforce his order.

According to the mayor, they will be using “disease detectives.” de Blasio explained, “It parallels what a police detective does. If someone has symptoms, they will literally interview them to figure out everywhere they’ve been, everyone they might have come in contact with, and then they go reach out to that whole network to make sure people are vaccinated.” It’s unclear whether “make sure people are vaccinated” means “hold them down and inject them against their will.”

https://explainlife.com/nyc-mayor-de-blasio-t...dium=email
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading